Table of Contents

Overview

Mutations in EP300 are significant contributors to the pathogenesis and progression of B-cell lymphomas such as DLBCL and FL.1 This gene has some recurrent sites of mutations (hot spots), which typically impact its HAT domain, a region crucial for acetylating histones and non-histone proteins.1

Experimental Evidence

EP300 mutations impair histone acetylation, disrupt epigenetic gene regulation. Mutations in CREBBP and EP300 affect a common pathway and have been described as mutually exclusive due to some functional redundancy.1,2 Studies using genome-wide CRISPR-Cas9 screens have identified synthetic lethal interactions between CREBBP and EP300, suggesting that targeting one may affect the viability of cells with mutations in the other.3

Relevance tier by entity

Entity Tier Description
MZL 1 high-confidence MZL gene4
DLBCL 1 high-confidence DLBCL gene supported by functional data1
FL 1 high-confidence FL gene supported by functional data1

Mutation incidence in large patient cohorts (GAMBL reanalysis)

Cannot include /DLBCL_EP300.md - does not exist yet

Cannot include /FL_EP300.md - does not exist yet

Mutation pattern and selective pressure estimates

Cannot include /dnds_EP300.md - does not exist yet

EP300 Hotspots

Chromosome Coordinate (hg19) ref>alt HGVSp
chr22 41566459 T>C Y1446H
chr22 41566460 A>G Y1446C
chr22 41566460 A>C Y1446S
chr22 41566462 A>T I1447F
chr22 41566466 T>G F1448C
chr22 41566474 C>T H1451Y
chr22 41566476 T>G H1451Q
chr22 41566478 C>T P1452L
chr22 41566486 C>G Q1455E
chr22 41566487 A>G Q1455R
chr22 41566488 G>T Q1455H
chr22 41566495 C>T P1458S
chr22 41566495 C>A P1458T
chr22 41566496 C>T P1458L
chr22 41566511 T>C L1463P
chr22 41566511 T>G L1463R
chr22 41566519 T>G W1466G
chr22 41566519 T>A W1466R
chr22 41566519 T>C W1466R
chr22 41566520 G>T W1466L
chr22 41566521 G>C W1466C
chr22 41566522 T>A Y1467N
chr22 41566522 T>C Y1467H
chr22 41566522 T>G Y1467D
chr22 41566523 A>G Y1467C
chr22 41566523 A>T Y1467F

View coding variants in ProteinPaint hg19 or hg38

View all variants in GenomePaint hg19 or hg38

EP300 Expression

Cannot include /mermaid_EP300.md - does not exist yet

References

1.
Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V, Kasper LH, Lerach S, Tang H, Ma J, Rossi D, Chadburn A, Murty VV, Mullighan CG, Gaidano G, Rabadan R, Brindle PK, Dalla-Favera R. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 2011 Mar 10;471(7337):189–195. PMCID: PMC3271441
2.
Veazey KJ, Cheng D, Lin K, Villarreal OD, Gao G, Perez-Oquendo M, Van HT, Stratton SA, Green M, Xu H, Lu Y, Bedford MT, Santos MA. CARM1 inhibition reduces histone acetyltransferase activity causing synthetic lethality in CREBBP/EP300-mutated lymphomas. Leukemia. 2020 Dec;34(12):3269–3285. PMCID: PMC7688486
3.
Nie M, Du L, Ren W, Joung J, Ye X, Shi X, Ciftci S, Liu D, Wu K, Zhang F, Pan-Hammarström Q. Genome-wide CRISPR screens reveal synthetic lethal interaction between CREBBP and EP300 in diffuse large B-cell lymphoma. Cell Death Dis. 2021 Apr 28;12(5):419. PMCID: PMC8080727
4.
Rossi D, Trifonov V, Fangazio M, Bruscaggin A, Rasi S, Spina V, Monti S, Vaisitti T, Arruga F, Famà R, Ciardullo C, Greco M, Cresta S, Piranda D, Holmes A, Fabbri G, Messina M, Rinaldi A, Wang J, Agostinelli C, Piccaluga PP, Lucioni M, Tabbò F, Serra R, Franceschetti S, Deambrogi C, Daniele G, Gattei V, Marasca R, Facchetti F, Arcaini L, Inghirami G, Bertoni F, Pileri SA, Deaglio S, Foà R, Dalla-Favera R, Pasqualucci L, Rabadan R, Gaidano G. The coding genome of splenic marginal zone lymphoma: Activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med. 2012 Aug 27;209(9):1537–1551. PMCID: PMC3428941

Citing

If you use the information or data from this site, please cite

Krysta Coyle, Kostiantyn Dreval, Daniel Hodson and Ryan D. Morin. Audit of B-cell cancer genes. Blood Adv (2025) 9 (8): 2019–2031.

Disclaimer

The content in these pages has been populated, in part, by an automated process. Although we have scrutinized every page to ensure accuracy, errors will inevitably exist. If you find an error please report it as an issue and we will address it.

License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

Share — copy and redistribute the material in any medium or format for any purpose, even commercially.

Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms.